<DOC>
	<DOCNO>NCT01691521</DOCNO>
	<brief_summary>This study evaluate two dose regimen mepolizumab [ 75mg intravenous ( i.v . ) 100mg subcutaneous ( SC ) every 4 week ] compare placebo 32 week treatment period subject severe refractory asthma elevate blood eosinophil . Efficacy measure reduction frequency asthma exacerbation . Additional efficacy assessment include measurement lung function , symptom score , quality life . Safety assess clinical laboratory sample , ECGs , immunogenicity adverse event . This study intend replicate Phase IIb/III study MEA112997 . Subjects MEA115588 , meet eligibility criterion screen visit , enter run-in period . Those subject able/eligible randomised end 6 week run-in period deem run-in failure . Subjects remain current maintenance therapy throughout run-in , double-blind treatment administration follow-up period . Subjects meet randomisation eligibility criterion randomise 1:1:1 ratio receive one follow treatment every 4 week total 8 dos : Mepolizumab 75 miligram ( mg ) i.v . placebo SC , Mepolizumab 100 mg SC placebo i.v . Placebo i.v . placebo SC . Subjects receive 8 dos double-blind treatment , meet eligibility criterion Open-Label Extension ( OLE ) Study , offer opportunity participate OLE trial .</brief_summary>
	<brief_title>Efficacy Safety Study Mepolizumab Adjunctive Therapy Subjects With Severe Uncontrolled Refractory Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Able give write informed consent prior participation study At least 12 year age visit 1 minimum weight 45 kilogram ( kg ) A welldocumented requirement regular treatment high dose inhale corticosteroid ( ICS ) 12 month prior Visit 1 without maintenance oral corticosteroid ( OCS ) Current treatment additional controller medication , besides ICS , least 3 month document failure past 12 month additional controller medication least 3 successive month Prior documentation eosinophilic asthma high likelihood eosinophilic asthma At Visit 1 , prebronchodilator FEV1 &lt; 80 % ( subject &gt; = 18 year age ) , prebronchodilator FEV1 &lt; 90 % FEV1 : FVC ratio &lt; 0.8 ( subject 1217 year age ) . Previously confirm history two exacerbation require treatment systemic CS Male Eligible Female ( female childbearing potential must commit consistent correct use acceptable method birth control ) French subject include either affiliated beneficiary social security category . Current smoker former smoker smoke history &gt; =10 pack year Presence know preexisting , clinically important lung condition asthma A current malignancy previous history malignancy le 12 month Known , preexist , unstable liver disease cirrhosis know biliary abnormality Known , preexist severe clinically significant cardiovascular disease know , preexist concurrent clinically significant medical condition uncontrolled standard treatment Subjects eosinophilic disease QTc ( F ) ≥450msec QTc ( F ) ≥480 msec A history alcohol/substance abuse Subject know immunodeficiency Subjects receive omalizumab within 130 day Visit 1 monoclonal antibody ( Xolair ) treat inflammatory disease within 5 halflives Visit 1 Subjects receive treatment investigational drug within past 30 day five terminal phase halflives drug whichever longer Subjects allergy/intolerance monoclonal antibody biologic . Subjects pregnant breastfeeding Subjects know evidence lack adherence controller medication and/or ability follow physician 's recommendation Previously participate study mepolizumab receive investigational product ( include placebo )</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>safety</keyword>
	<keyword>SB-240563</keyword>
	<keyword>efficacy</keyword>
	<keyword>placebo</keyword>
	<keyword>eosinophil</keyword>
	<keyword>mepolizumab</keyword>
	<keyword>Severe refractory asthma</keyword>
</DOC>